Abstract: An intelligent storage system for a sample repository is provided, including at least one group of storage modules (1) and at least one group of extraction modules (2). The storage module (1) includes at least two storage tanks (3). Access ports (4) are formed in upper end surfaces of the storage tanks (3), and positions of the access ports (4) of two corresponding storage tanks (3) correspond to each other. The extraction modules (2) are disposed above the storage modules (1), and are capable of extracting or storing cryopreservation tubes and/or storage racks in the storage tanks (3) via the access ports (4). The storage modules (1) can be connected by means of multiple types of transfer devices to quickly transfer and transport samples and to provide an emergency solution.

Abstract: A driving substrate, including: a base; a first insulating layer and first conductive wires on the base; the first insulating layer is provided with openings, the first conductive wires are positioned in the openings, and at any position in a lengthwise direction of the first conductive wires, each side surface of each first conductive wire is in contact with a side surface of the opening, where said each first conductive wire is positioned, at least at a partial height; each first conductive wire includes a seed wire and a growth wire; second conductive wires positioned on a side of the first conductive wires away from the base, each second conductive wire is coupled to one first conductive wire and is provided with a coupling area for coupling a light-emitting unit. A method for manufacturing the driving substrate, a light-emitting substrate and a display device are further provided.

Abstract: A cellulose acetate particle aggregate, a preparation method therefor and an application thereof, which relate to the field of harm reduction additives in cigarettes. The cellulose acetate particle aggregate includes 49-99.5 wt % of cellulose acetate particles, 0-50 wt % of a second kind of particles, and 0.5-20 wt % of a binder. The preparation method involves selecting cellulose acetate particles and a second kind of particles in a certain ratio, or cellulose acetate particles alone, preparing particle aggregates by using an air fluidized granulation method while adding a binder thereto, and sieving the particle aggregates to obtain a cellulose acetate particle aggregate having a required particle size. The cellulose acetate particle aggregate has a porous structure, an irregular shape, and a rough and uneven surface, which help to improve the efficiency of filtering out particulate matters or one or more harmful ingredients in cigarette smoke.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: An aerosol generating product includes an aerosol atomizing element and a smoke cooling element, and the smoke cooling element is located downstream of the flow direction of the smoke generated by the aerosol atomizing element. A filter element is located downstream of the flow direction of the smoke through which the smoke cooling element passes; or a hollow element located upstream of the flow direction of the smoke through which the smoke cooling element passes. The smoke cooling element is composed of particles, and the structure includes a gap for smoke of a cigarette to pass through. The gap through which cigarette smoke can pass is a three-dimensional and non-linear gap. The structure is in the form of rods. When the smoke aerosol passes through the cooling element, ensuring the smoke to pass through smoothly.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: The present disclosure relates to a surgical electrode assembly comprising: an electrode device comprising electrodes; a manipulating device; an electrode driving device configured to drive the electrodes, the manipulating device comprising an actuation mechanism; an inner tube having an inner tube proximal portion at a proximal end thereof, an inner tube distal portion at a distal end thereof, and an inner tube bending portion therebetween, the inner tube bending portion having a curvature, such that the inner tube distal portion and the inner tube proximal portion are disposed at an angle to each other; an outer tube having an outer tube proximal portion at a proximal end thereof and an outer tube distal portion at a distal end thereof, and an outer tube connecting portion therebetween, wherein the outer tube connecting portion is adapted to the inner tube bending portion, such that when manipulating the manipulating device to cause the inner tube and the outer tube to move relative to each other, the outer

Abstract: A cellulose acetate particle aggregate, a preparation method therefor and an application thereof, which relate to the field of harm reduction additives in cigarettes. The cellulose acetate particle aggregate includes 49-99.5 wt % of cellulose acetate particles, 0-50 wt % of a second kind of particles, and 0.5-20 wt % of a binder. The preparation method involves selecting cellulose acetate particles and a second kind of particles in a certain ratio, or cellulose acetate particles alone, preparing particle aggregates by using an air fluidized granulation method while adding a binder thereto, and sieving the particle aggregates to obtain a cellulose acetate particle aggregate having a required particle size. The cellulose acetate particle aggregate has a porous structure, an irregular shape, and a rough and uneven surface, which help to improve the efficiency of filtering out particulate matters or one or more harmful ingredients in cigarette smoke.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: A cellulose acetate particle aggregate, a preparation method therefor and an application thereof, which relate to the field of harm reduction additives in cigarettes. The cellulose acetate particle aggregate includes 49-99.5 wt % of cellulose acetate particles, 0-50 wt % of a second kind of particles, and 0.5-20 wt % of a binder. The preparation method involves selecting cellulose acetate particles and a second kind of particles in a certain ratio, or cellulose acetate particles alone, preparing particle aggregates by using an air fluidized granulation method while adding a binder thereto, and sieving the particle aggregates to obtain a cellulose acetate particle aggregate having a required particle size. The cellulose acetate particle aggregate has a porous structure, an irregular shape, and a rough and uneven surface, which help to improve the efficiency of filtering out particulate matters or one or more harmful ingredients in cigarette smoke.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.